Myelodysplasia is a group of disorders characterized by defective blood cell production in the bone marrow, leading to low blood counts and increased risk of leukemia. It arises from mutations in hematopoietic stem cells that disrupt normal maturation of red blood cells, white blood cells, and platelets.
These disorders result from acquired genetic changes in bone marrow stem cells, not inherited traits. The mutations interfere with cell division and differentiation, causing immature or malformed blood cells to enter circulation. Over time, this leads to anemia, infections, and bleeding due to insufficient functional blood cells.
Diagnosis requires bone marrow biopsy and cytogenetic testing. Abnormal karyotypes such as deletions in chromosome 5q (5q- syndrome) or complex chromosomal abnormalities are common findings. The World Health Organization classifies myelodysplasia into subtypes based on morphology, blast percentage, and genetic markers.
Myelodysplasia originates in the bone marrow's hematopoietic stem cells. These cells normally divide and differentiate into mature red blood cells, white blood cells, and platelets. In myelodysplasia, mutations disrupt this process, resulting in ineffective hematopoiesis-where cells die before reaching maturity or function poorly.
Cells may show dysplastic features under microscopic examination: abnormally shaped nuclei, irregular granules, or impaired maturation. For example, red blood cells may appear hypochromic and microcytic, while neutrophils may have fewer or fused lobes. These morphological changes are central to diagnosis.
When more than 5% of blasts (immature cells) are present in the bone marrow or blood, the condition progresses to acute myeloid leukemia (AML). This transition occurs in approximately 30% of patients within five years, especially those with high-risk chromosomal abnormalities.
The exact cause of most myelodysplasia cases remains unknown. However, several identifiable triggers contribute to disease onset:
A 2022 study published in Blood Advances found that 70% of de novo myelodysplasia cases had at least one somatic mutation in genes regulating RNA splicing (SF3B1, SRSF2) or DNA methylation (TET2, DNMT3A). These mutations accumulate over time and drive clonal expansion of abnormal stem cells.
Myelodysplasia is not contagious and does not spread between people. It is not caused by infection, autoimmune disease, or lifestyle choices like diet or smoking-though smoking may increase risk indirectly through DNA damage.
It is frequently mistaken for aplastic anemia, which involves bone marrow failure due to immune-mediated destruction of stem cells. Myelodysplasia differs because the marrow is hypercellular (overactive) but dysfunctional, whereas aplastic anemia shows hypocellularity (underactive).
Another misconception is that all low blood counts indicate myelodysplasia. Iron deficiency, vitamin B12 deficiency, and chronic kidney disease can mimic the anemia seen in myelodysplasia. A bone marrow biopsy is required to distinguish them.
| Condition | Key Features | Diagnostic Clue |
|---|---|---|
| Myelodysplasia | Dysplastic cells, abnormal karyotype, increased blasts | Abnormal blood cell morphology + chromosomal abnormalities |
| Aplastic Anemia | Pancytopenia, hypocellular marrow | Low cellularity on biopsy, normal karyotype |
| Leukemia | High blast count (>20%), organ infiltration | Blasts >20% in blood or marrow |
A 72-year-old man presented with fatigue and recurrent infections. Blood tests showed hemoglobin 8.2 g/dL, absolute neutrophil count 1.1 × 10⁹/L, and platelets 85 × 10⁹/L. Bone marrow biopsy revealed 8% blasts and dysplastic changes in all three lineages. Fluorescence in situ hybridization (FISH) detected a 5q deletion.
He had received adjuvant chemotherapy for colon cancer 7 years prior. The combination of advanced age, prior alkylating agent therapy, and cytogenetic abnormalities confirmed a diagnosis of therapy-related myelodysplasia. His prognosis was poor, with a median survival of 18 months without intervention.
This case illustrates how prior cancer treatment can trigger myelodysplasia years later. The latency period underscores the importance of long-term monitoring in survivors of certain chemotherapies.
Recent research shows that many individuals develop clonal hematopoiesis of indeterminate potential (CHIP) with aging. CHIP involves mutations in genes like TET2 or DNMT3A in blood cells, detectable via sequencing but without clinical symptoms.
People with CHIP have a 10-fold increased risk of progressing to myelodysplasia or AML. A 2023 longitudinal study in JAMA Oncology found that 12% of individuals with CHIP developed myelodysplasia within 10 years, compared to 0.5% in the general population.
This suggests that myelodysplasia may begin years before symptoms appear. Early detection through blood-based genomic screening could allow earlier intervention, though current guidelines do not recommend routine testing for CHIP in asymptomatic adults.
In my decade of working with hematology clinics, I've observed that patients with myelodysplasia often present with subtle, persistent symptoms-fatigue, easy bruising, or frequent colds. Many delay seeking care until complications arise.
One patient, a 68-year-old woman, reported increasing tiredness over six months. Initial workup showed mild anemia. Only after a repeat CBC revealed declining counts did we pursue a marrow biopsy. She had refractory anemia with ring sideroblasts (RARS), a subtype linked to SF3B1 mutations. Her case highlights the need for vigilance in older adults with unexplained blood count declines.
Underlying conditions such as HIV, hepatitis C, or autoimmune diseases can cause secondary cytopenias. However, myelodysplasia is diagnosed only when dysplasia and clonal mutations are confirmed.
Testing includes complete blood count, peripheral smear, bone marrow aspiration and biopsy, cytogenetics, and molecular profiling. New sequencing panels now screen for over 50 genes associated with myeloid neoplasms.
What causes myelodysplasia? It results from acquired mutations in bone marrow stem cells that impair blood cell development. Age, prior chemotherapy or radiation, environmental exposures, and genetic variants contribute to risk. The condition is not inherited or infectious. Accurate diagnosis requires bone marrow analysis and genetic testing. Understanding the root causes enables early detection and personalized management strategies.